|
Q2 FY2027
As of Jul 31, 2026
|
Q1 FY2027
As of Apr 30, 2026
|
Q4 FY2026
As of Jan 31, 2026
|
Q3 FY2026
As of Oct 31, 2025
|
Q2 FY2026
As of Jul 31, 2025
|
Q1 FY2026
As of Apr 30, 2025
|
Q4 FY2025
As of Jan 31, 2025
|
Q3 FY2025
As of Oct 31, 2024
|
Q2 FY2025
As of Jul 31, 2024
|
Q1 FY2025
As of Apr 30, 2024
|
Q4 FY2024
As of Jan 31, 2024
|
Q3 FY2024
As of Oct 31, 2023
|
Q2 FY2024
As of Jul 31, 2023
|
Q1 FY2024
As of Apr 30, 2023
|
Q4 FY2023
As of Jan 31, 2023
|
Q3 FY2023
As of Oct 31, 2022
|
Q2 FY2023
As of Jul 31, 2022
|
Q1 FY2023
As of Apr 30, 2022
|
Q4 FY2022
As of Jan 31, 2022
|
Q3 FY2022
As of Oct 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Short-term investments | ||||||||||||||||||||
| Accounts receivable, net of allowance of $14,000 as of July 31, 2026 and $16,000 as of January 31, 2026 | ||||||||||||||||||||
| Inventories | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and Stockholders’ Equity (Deficit) | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued and other current liabilities | ||||||||||||||||||||
| Deferred revenue, current | ||||||||||||||||||||
| Debt, current | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Deferred revenue, noncurrent | ||||||||||||||||||||
| Debt, noncurrent | ||||||||||||||||||||
| Operating lease liabilities | ||||||||||||||||||||
| Deferred tax liabilities | ||||||||||||||||||||
| Other long-term liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Redeemable convertible preferred stock: $0.0001 par value; zero and 0 shares authorized as of January 31, 2024 and 2023, respectively; zero and 0 shares issued and outstanding as of January 31, 2024 and 2023, respectively (liquidation value: nil and $0 as of January 31, 2024 and 2023, respectively) | ||||||||||||||||||||
| Stockholders’ equity (deficit): | ||||||||||||||||||||
| Common stock: $0.0001 par value; 1,000,000,000 shares authorized as of each of July 31, 2026 and January 31, 2026; 26,850,324 and 24,316,597 shares issued and outstanding as of July 31, 2026 and January 31, 2026, respectively | ||||||||||||||||||||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of each of July 31, 2026 and January 31, 2026; zero shares issued and outstanding as of July 31, 2026 and January 31, 2026 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive income (loss) | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders’ equity (deficit) | ||||||||||||||||||||
| Total liabilities and stockholders’ equity (deficit) | ||||||||||||||||||||
| Preferred stock, shares authorized (in shares) | ||||||||||||||||||||
| Common stock, shares authorized (in shares) | ||||||||||||||||||||
Loading...
